Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Invested Capital (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Invested Capital for 6 consecutive years, with $151.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 483.35% year-over-year to $151.5 million, compared with a TTM value of $151.5 million through Dec 2025, up 483.35%, and an annual FY2025 reading of $151.5 million, up 483.35% over the prior year.
  • Invested Capital was $151.5 million for Q4 2025 at SAB Biotherapeutics, down from $165.1 million in the prior quarter.
  • Across five years, Invested Capital topped out at $165.1 million in Q3 2025 and bottomed at $12.0 million in Q2 2025.
  • Average Invested Capital over 5 years is $46.8 million, with a median of $37.0 million recorded in 2022.
  • Peak annual rise in Invested Capital hit 483.35% in 2025, while the deepest fall reached 73.95% in 2025.
  • Year by year, Invested Capital stood at $42.5 million in 2021, then fell by 18.02% to $34.8 million in 2022, then skyrocketed by 64.56% to $57.3 million in 2023, then plummeted by 54.68% to $26.0 million in 2024, then skyrocketed by 483.35% to $151.5 million in 2025.
  • Business Quant data shows Invested Capital for SABS at $151.5 million in Q4 2025, $165.1 million in Q3 2025, and $12.0 million in Q2 2025.